Case Report

Risk Factors and Epidemiology of Coccidioidomycosis Demonstrated by a Case of Spontaneous Pulmonary Rupture of Cavitary Coccidioidomycosis

Amy A. Yau

Internal Medicine, William Beaumont Army Medical Center, 5005 North Piedras Street, El Paso, TX 79920, USA

Correspondence should be addressed to Amy A. Yau; amy.a.yau.mil@mail.mil

Received 15 September 2015; Accepted 30 December 2015

Academic Editor: Sandeep Dogra

Copyright © 2016 Amy A. Yau. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Coccidioidomycosis is prevalent in the southwestern United States. However due to migration and travel, cases have been reported across the world and with increasing frequency. Data from the Centers for Disease Control demonstrate an increased incidence from 5.3 per 100,000 population in 1998 to 42.6 per 100,000 population in 2011 [1]. This approximates a 16% annual increased incidence. In endemic regions, Coccidioides species are responsible for 15–30% of community-acquired pneumonia [2]. This dimorphic fungus is found in soil; thus cases in endemic regions spike after rainy seasons (i.e., spring, end of summer) and natural or man-related activities that disturb the environment (i.e., dust storms, earthquakes, excavations, and construction). Coccidioides infection, also known as Valley Fever, was first described after multiple cases of patients became infected from Coccidioides immitis in the San Joaquin Valley area in California; however it is endemic throughout the desert southwest United States.

A second species, Coccidioidomycosis posadasii, is genetically different but presents similarly in the same endemic regions. As more cases appear, it is important for clinicians to have a high index of suspicion and understand full spectrum of disease and rare complications that can occur.

2. Case Presentation

A 31-year-old previously healthy male presented for two weeks of fevers, productive cough, and pleurisy. Symptom onset followed recent wisdom tooth extraction and travel to Juarez, Mexico, for construction work. He is a resident of El Paso, Texas. On admission he was febrile, and chest auscultation revealed left basilar crackles.

His laboratory findings revealed a white blood cell count of 13.0 K/μL, and chest radiography demonstrated a 4.4 cm cavitary lesion (Figure 1). Further evaluation via chest CT revealed an air fluid level (Figure 2), left hilar and mediastinal...
lymphadenopathy, and bilateral tree-in-bud and nodular opacities. Bronchoscopic evaluation did not reveal bronchial abnormalities, but cultures from lavage grew *Haemophilus influenza* and Group F *Streptococcus*. He was diagnosed with a necrotizing pneumonia and discharged with amoxicillin clavulanate after resolution of his fever and leukocytosis.

Five days later he returned with recurrent fevers and dry cough. He complained of new acute dyspnea and worsening of pleurisy after a coughing fit. He denied arthralgias. He was febrile up to 103.0°F with otherwise stable vitals. Pulmonary exam was significant for absent breath sounds on the left, splinting, and midline trachea. There were no meningeval signs or skin lesions. His white blood cell count was 17.5 K/μL. Chest radiograph on this admission showed left sided pyopneumothorax (Figure 3).

Our patient was readmitted and a chest tube placed. Repeat chest CT demonstrated worsening of disease via extension of pulmonary opacities and lymphadenopathy. Repeat respiratory cultures grew *Enterococcus cloacae*, but he did not respond to broad spectrum antibiotics and had persistent fever and leukocytosis. Multiple acid fast bacilli stains and cultures remained negative. Direct fluorescent assay for *Pneumocystis jirovecii*, *Cryptococcus* antigen, and galactomannan antigen for *Aspergillus* were negative.

Serology sent during his first hospitalization due to high suspicion returned ID-TP and ID-CF positive for *Coccidioidomycosis immitis* with titers 1:16 and 1:8, respectively. He was started on fluconazole but underwent superior segmentectomy due to persistent air leak. Interestingly segmented tissue did not stain positively for any organism, and over a month later, lavage and intraoperative pleural fluid cultures grew *Coccidioidomycosis immitis*. The patient demonstrated continued improvement and was treated with an extended course of fluconazole followed by local specialists.

### 3. Discussion

Our patient presented multiple confounders to his eventual diagnosis. Despite living and working in an endemic area, his history of oral surgery and response to antibiotics were red herrings to the culprit, *Coccidioidomycosis immitis*. Additionally, the dramatic nature of his disease prompted screening for dissemination, HIV, and quantitative immunodeficiencies. All were negative. During his hospital course, the patient was diagnosed with diabetes, and that coupled with his reported ethnicity of being Hispanic and geographical and environmental risk factors made coccidioidomycosis high on the differential. However as described below with the rarity of ruptured coccidioidomycosis pulmonary cavities and delay in diagnosis through serum and direct culture analysis, treatment can often be delayed.

Many patients with coccidioidal pneumonia are minimally troubled and do not seek medical treatment. Approximately 60% of infected patients will have nonspecific respiratory symptoms and significant fatigue one to three weeks after exposure [3]. Coccidioidomycosis can also manifest as nodules and cavitary disease. Asymptomatic pulmonary cavities are monitored [4]. Seen in 10–15% of patients with coccidioidomycosis, half of these cases demonstrate radiographic resolution without treatment [5]. The disease is considered noncontagious as inhaled arthroconidia, only 3–6 μm in diameter, maneuver down terminal bronchioles and settle in alveoli [6]. There they proliferate into endospores and spherules, which are 20–60 μm in diameter and too large to be brought up by expectoration [6]. Because of the periphery of the infection, pleuritic chest pain is often associated [7].
as seen with our patient. Other symptoms include fatigue, arthralgias, erythema nodosum, and erythema multiforme, and more symptomatic patients go on to seek medical care. Disseminated coccidioidal mycosis is seen in less than five percent of cases and is typically seen in immunosuppressed groups, such as patients receiving high dose steroids or immunomodulators; patients with human immunodeficiency (HIV) infections; or patients with transplanted organs.

Other than immunosuppressed populations, there are other populations at increased risk for significant and symptomatic pulmonary disease. Patients with diabetes have a relative risk of 2.94 for development of cavitary disease compared to their nondiabetic counterparts [5, 8]. Poorly controlled diabetics carry an increased risk of relapsing and disseminated disease [8]. Complicated pulmonary disease, defined by nonresolving cavitation, cavitary rupture, and pyopneumothorax, requires surgical repair, and a quarter of these patients are diabetic [4, 9]. Epidemiologic data demonstrates Hispanics and African American individuals have a higher incidence of coccidioidal disease compared to their population [2]. Given most cases are asymptomatic, the increased case numbers suggest these demographics are more symptomatic and thus seek out medical care more than other demographics. Further data show Filipino and African American patients see more dissemination [1, 2, 10], and Hispanics and Native Americans have a higher age adjustment mortality compared to Caucasian counterparts [11].

These populations, specifically diabetics, may be at more risk due to their immunocompromised state compared to the general healthy population. *Coccidioides immitis* arthroconidia are phagocytized and induce a humoral immune response. S cell walls are hydrophobic and are hypothesized to release a protease that renders humoral mediated immune response negligible [7]. Dermal type IV hypersensitivity reactions and INFγ mediated endospore destruction support the importance of cell mediated immunity [7]. Interestingly, cellular immunity is inhibited in diabetic patients as hyperglycemia has been shown to inhibit maturation of dendritic cells and modify function of cytokines, such as IFNγ.

Despite known risk factors for severe disease, because of rarity of ruptured cavitary disease it is difficult to characterize risk factors for this population. Pleural effusions develop in 15% of patients infected [12], but pyopneumothoraces from spontaneous cavitary rupture are exceedingly rare. These episodes are described in healthy athletic males [13] and thought to occur in only 2.6% of cavitary coccidioidomycosis [9, 10]. Even more rare is the development of bronchopleural fistulas, which occur in one-eighth of these ruptured cavities [10].

Diagnosis requires understanding the manifestations of coccidioidomycosis and high suspicion in nonendemic regions. Although formation of antibodies may not be protective, the presence of serology can be used for diagnosis, and titers can prognosticate aggregation of disease. Immunodiffusion to tube precipitin (ID-TP) is measurable within one to three weeks of onset, and immunodiffusion to complement fixing antigen (ID-CF) is measurable two to three weeks after inoculation and can be quantified. Immunoglobulin G (IgG) to CF titers more than 1:16 suggest severe disease [4]. Both methods are highly sensitive and specific, although repeat positive serologies increase their sensitivity; however results can take weeks to return depending on reference laboratories being used.

Gold standard for diagnosis is culture and/or species identification. *Coccidioides* species are cultured best from pleural biopsy with rare positivity on sputum and pleural fluid cultures. Fine needle aspiration (FNA) biopsies can yield spherule and rare mycelia forms [14], and bronchoalveolar lavage (BAL) will often demonstrate eosinophilia with positive mycelia seen on culture in 30–64% of specimens [15]. Cultured organisms are not specific and require confirmation with DNA probe and/or sequencing, which can take many weeks. Additionally, cultures must be handled carefully by certain laboratories given high risk for inhalation by laboratory workers of arthroconidia.

Treatment is recommended in symptomatic patients, patients with multiple comorbidities, high risk factors, or dissemination. Fluconazole is the azole of choice for most pneumonia and cavitary disease except for the pregnant patient, for whom amphotericin B is necessary [4]. Rare ruptured pulmonary cavities are treated surgically with lobectomy and decortication (AII recommendation). Despite these recommendations, there have been no randomized controlled trials showing if early treatment of uncomplicated pneumonia prevents morbidity or hastens recovery. Because of high suspicion and multiple risk factors for disseminated and presentation with complicated disease, our patient was started on fluconazole therapy while pending serum and culture confirmation. Perhaps increased awareness and economic impact analyses will prompt such research to help answer these questions.

**Disclaimer**

The views expressed in this document are those of the author and do not reflect the official policy of William Beaumont Army Medical Center, the Department of the Army, or the United States Government.

**Conflict of Interests**

The author declares that there is no conflict of interests regarding the publication of this paper.

**References**

[1] Centers for Disease Control and Prevention, "Increase in reported coccidioidomycosis—United States, 1998–2011," *Morbidity and Mortality Weekly Report*, vol. 62, no. 12, pp. 217–221, 2013.

[2] R. F. Hector, G. W. Rutherford, C. A. Tsang et al., "The public health impact of coccidioidomycosis in Arizona and California," *International Journal of Environmental Research and Public Health*, vol. 8, no. 4, pp. 1150–1173, 2011.

[3] N. M. Ampel, "Coccidioidomycosis: a review of recent advances," *Clinics in Chest Medicine*, vol. 30, no. 2, pp. 241–251, 2009.
[4] J. H. Galgiani, N. M. Ampel, J. E. Blair et al., “Coccidioidomycosis,” Clinical Infectious Diseases, vol. 41, no. 9, pp. 1217–1223, 2005.

[5] L. B. Gadkowski and J. E. Stout, “Cavitary pulmonary disease,” Clinical Microbiology Reviews, vol. 21, no. 2, pp. 305–333, 2008.

[6] R. P. Murray, K. S. Rosenthal, and M. A. Pfaller, Medical Microbiology, Mosby, St. Louis, Mo, USA, 7th edition, 2012.

[7] J. N. Galgiani, “Coccidioidomycosis,” Western Journal of Medicine, vol. 159, no. 2, pp. 153–171, 1993.

[8] A. C. Santelli, J. E. Blair, and L. R. Roust, “Coccidioidomycosis in patients with diabetes mellitus,” The American Journal of Medicine, vol. 119, no. 11, pp. 964–969, 2006.

[9] D. E. Jaroszewski, W. J. Halabi, J. E. Blair et al., “Surgery for pulmonary coccidioidomycosis: a 10-year experience,” Annals of Thoracic Surgery, vol. 88, no. 6, pp. 1765–1772, 2009.

[10] C. E. Smith, R. R. Beard, and M. T. Saito, “Pathogenesis of coccidioidomycosis with special reference to pulmonary cavitiation,” Annals of Internal Medicine, vol. 29, no. 4, pp. 623–655, 1948.

[11] J. Y. Huang, B. Bristow, S. Shafir, and F. Sorvillo, “Coccidioidomycosis-associated deaths, United States, 1990–2008,” Emerging Infectious Diseases, vol. 18, no. 11, pp. 1723–1728, 2012.

[12] M. Merchant, A. O. Romero, R. D. Libke, and J. Joseph, “Pleural effusion in hospitalized patients with coccidioidomycosis,” Respiratory Medicine, vol. 102, no. 4, pp. 537–540, 2008.

[13] J. Galgiani, K. Knox, C. Rundbaken, and J. Siever, “Common mistakes in managing pulmonary coccidioidomycosis,” Southwest Journal of Pulmonary and Critical Care, vol. 10, no. 5, pp. 238–249, 2015.

[14] B. Muñoz-Hernández, M. A. Martinez-Rivera, G. P. Cortés, A. Tapia-Díaz, and M. E. M. Zavala, “Mycelial forms of Coccidioides spp. in the parasitic phase associated to pulmonary coccidioidomycosis with type 2 diabetes mellitus,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 27, no. 9, pp. 813–820, 2008.

[15] J. Malo, C. Luraschi-Monjagatta, D. M. Wolk, R. Thompson, C. A. Hage, and K. S. Knox, “Update on the diagnosis of pulmonary coccidioidomycosis,” Annals of the American Thoracic Society, vol. 11, no. 2, pp. 243–253, 2014.